Safety and immunogenicity of UBI HIV-1(MN) octameric V3 peptide vaccine administered by subcutaneous injection

AIDS Research and Human Retroviruses

Volumn 13, Issue 1, 1997, Pages 29-32

  Kelleher, Anthony D ^a   Emery, Sean ^b   Cunningham, Philip ^a   Duncombe, Christopher ^c   Carr, Andrew ^a   Golding, Helen ^a   Forde, Sally ^b   Hudson, Jeff ^b   Roggensack, Monika ^a   Forrest, Bruce D ^d,e   Cooper, David A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Holdsworth House General Practice   (Australia)

^d United Biomedical Inc   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIGEN RECOGNITION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 18244420800     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.29     Document Type: Article

References (19)

1. Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablein DM, Smith GE, and Koff WC: The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991;114:119-127.
2. Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege A-M, Berman P, Twaddell T, Stablein D, Sposto R, Siliciano R, and Matthews T: Induction of HIV-1 neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
3. Kovacs JA, Vasudevarhari MB, Easter M, Davey RT, Fallon J, Polis MA, Metcalf JA, Sazman N, Baseler M, and Smith GE: Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest 1993; 92:919-928.
4. Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, and Reichman RC: Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis 1991;163:448-453.
5. Wintsch J, Chaignat CL, Braun DG, Jeanett M, Stadler H, Abrignani S, Mantagna D, Clavijo F, Moret P, and Dayer JM: Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis 1991;163:219-225.
6. Wang CY, Looney DJ, Li MC, Walfield AM, Ye J, Hosein B, Tam JP, and Wong-Staal F: Long term high titer neutralising activity induced by octameric synthetic HIV-1 antigen. Science 1991;254:285-288.
7. Walfield A, Li M, Hosein B, Ye J, Looney D, Wong-Staal F, Morton W, Schmidt A, and Wang CY: High-titer neutralization for multiple HIV-1 isolates by branched immunogens. In: VIIIth International Conference on AIDS/III STD World Congress. Amsterdam, The Netherlands, July 19-24, 1992. [Abstract POA 2233]
8. MN V3 branched peptide vaccine. J Infect Dis 1996;173:330-339.
9. MN octameric peptide vaccine in HIV-1 negative adults. In: Xth International Conference on AIDS/Vth STD World Congress. Yokohama, Japan, August 7-12, 1994. [Abstract 318A]
10. Wahren B, Rosen J, Sandstrom E, Mathiesen T, Modrow S, and Wigzell H: HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J Acquir Immun Defic Syndr 1989;4:448-456.
11. Kelleher AD, Carr A, Zaunders J, and Cooper DA: Alterations in the immune response of HIV-infected subjects treated with a HIV-specific Protease inhibitor, Ritonavir. J Infect Dis 1996;173:321-329.
12. Centers for Disease Control: Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR 1985;34:105-113.
13. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, and Lemon SM: Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985;254(22):3187-3189.
14. Yamamoto S, Kuriko T, Kurai K, and Iino S: Comparison of results for phase I studies with recombinant and plasma-derived hepatitis B vaccines, and controlled study comparing intramuscular and subcutaneous injections of recombinant hepatitis B vaccine. J Infect Dis 1586;13(Suppl. A):53-60.
15. Vyakarnam A, Matear PM, Cranenberg C, Michie C, Beverly PCL, Wahren B, Gill SK, and Weller I: T-cell responses to peptides covering gag p24 region of HIV-1 occur in HIV-1 sero-negative individuals. Int Immunol 1991;10:939-947.
16. Clerici M, Berzofsky JA, Shearer GM, and Tacket CO: Exposure to human immunodeficiency virus type 1-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J Infect Dis 1991;164:178-182.
17. Kelker HC, Seidlin M, Volger M, and Valentine FT: Lymphocytes from some long-term seronegative heterosexual partners of HIV-1 infected individuals proliferate in response to HIV antigens. AIDS Res Hum Retroviruses 1992;8:1355-1359.
18. Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, Lahdvirta J, and Krohn K: T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989;3:63-69.
19. Clerici M, Tacket CO, Via CS, Lucey DR, Muluk SC, Zajac RA, Boswell RN, Berzosky JA, and Shearer GM: Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol 1991;21:1345-1349.